Halozyme Therapeutics, Inc. (BMV:HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions MXN. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 5, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	162,637	126,748	82,540	150,073	116,003	114,707
Market Cap Growth	13.37%	53.56%	-45.00%	29.37%	1.13%	134.71%
Enterprise Value	177,018	144,848	100,236	174,383	117,299	115,751
Last Close Price	1395.66	680.00	680.00	679.74	775.07	-
PE Ratio	14.89	13.70	17.34	38.06	14.05	44.66
PS Ratio	7.13	5.99	5.89	11.66	12.76	21.54
PB Ratio	17.60	16.72	58.26	45.31	28.73	38.17
P/TBV Ratio	-	-	-	-	28.73	38.17
P/FCF Ratio	14.72	12.99	13.08	32.70	18.99	108.87
P/OCF Ratio	14.51	12.70	12.57	32.04	18.90	103.95
EV/Sales Ratio	8.29	6.85	7.15	13.54	12.91	21.74
EV/EBITDA Ratio	12.53	11.09	14.22	26.60	20.63	39.89
EV/EBIT Ratio	13.97	12.61	17.43	30.89	20.74	40.33
EV/FCF Ratio	16.02	14.84	15.88	37.99	19.20	109.86
Debt / Equity Ratio	3.05	4.22	18.27	9.07	4.47	2.66
Debt / EBITDA Ratio	1.87	2.42	3.59	4.54	3.15	2.71
Debt / FCF Ratio	2.56	3.28	4.10	6.55	2.95	7.59
Asset Turnover	0.57	0.54	0.46	0.45	0.53	0.47
Inventory Turnover	1.65	1.77	2.36	2.67	2.04	1.72
Quick Ratio	1.25	6.50	5.07	4.54	7.10	1.11
Current Ratio	1.59	7.80	6.64	5.65	7.91	1.32
Return on Equity (ROE)	124.50%	198.42%	222.07%	110.23%	231.44%	106.33%
Return on Assets (ROA)	21.24%	18.16%	11.89%	12.28%	20.47%	15.74%
Return on Invested Capital (ROIC)	44.20%	34.03%	20.93%	27.92%	105.98%	108.82%
Return on Capital Employed (ROCE)	53.30%	28.70%	21.00%	16.90%	27.90%	91.00%
Earnings Yield	6.72%	7.30%	5.77%	2.63%	7.12%	2.24%
FCF Yield	6.79%	7.70%	7.65%	3.06%	5.27%	0.92%
Buyback Yield / Dilution	3.31%	3.56%	4.56%	4.21%	-3.77%	1.99%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.